Welcome to our dedicated page for Capitol Federal SEC filings (Ticker: CFFN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Capitol Federal turns hometown deposits into first-lien mortgages is crucial, yet its 200-page disclosures can feel like wading through footnotes on risk-based capital. If you have ever asked, “Where can I find Capitol Federal quarterly earnings report 10-Q filing?� or "How do I decode the bank’s interest-rate sensitivity table?" you know the challenge.
Stock Titan solves that problem. Our platform delivers Capitol Federal SEC filings explained simply with AI-powered summaries that pull out net-interest margin swings, credit-quality metrics and deposit-mix changes in seconds. Whether it’s a sudden Capitol Federal 8-K material events explained or a detailed Capitol Federal annual report 10-K simplified, you get real-time alerts the moment EDGAR posts.
Here’s what you can do on this page:
- Monitor Capitol Federal Form 4 insider transactions real-time and spot buying or selling trends.
- Review each Capitol Federal insider trading Form 4 transactions filing with AI commentary on executive conviction.
- Dive into every Capitol Federal earnings report filing analysis to compare quarter-over-quarter loan growth.
- See how the Capitol Federal proxy statement executive compensation aligns pay with return on equity.
The result: informed decisions without combing through endless tables. From Capitol Federal executive stock transactions Form 4 to the next call-report-driven footnote, Stock Titan streamlines understanding Capitol Federal SEC documents with AI so you can focus on assessing credit risk and dividend sustainability, not parsing legalese.
Elevation Oncology (ELEV) filed Amendment No. 1 to its Schedule 14D-9 to report the final results and closing of the previously announced tender offer by Concentra Biosciences� subsidiary, Concentra Merger Sub VI.
- Consideration: $0.36 cash + one non-transferable contingent value right (CVR) per share.
- Expiration: 11:59 p.m. ET on 22 Jul 2025; 39,773,172 shares tendered, representing 67.09 % of outstanding shares.
- Conditions: Minimum tender and all other conditions were satisfied or waived; Purchaser has irrevocably accepted all validly tendered shares and will promptly pay the offer price.
- Merger completion: Having surpassed the Section 251(h) threshold, Purchaser consummated the merger on 23 Jul 2025 without a shareholder vote.
- Each remaining share (subject to limited treasury, appraisal and parent-owned exceptions) was cancelled and converted into the right to receive the same cash-plus-CVR consideration, less any withholding taxes.
- Delisting: Trading in ELEV shares ceased prior to the Nasdaq open on 23 Jul 2025; the shares will be delisted and deregistered under the Exchange Act.
The amendment contains no other material changes beyond the confirmation of offer results and merger closing.
FAQ
What is the current stock price of Capitol Federal (CFFN)?
What is the market cap of Capitol Federal (CFFN)?
What is the core business of Capitol Federal?
How does Capitol Federal generate its revenue?
What products and services are offered by Capitol Federal?
What regions does Capitol Federal primarily serve?
How does Capitol Federal ensure financial stability?
How is Capitol Federal positioned within the competitive landscape?
